<body><p>HR 413 IH</p><p/><center><p>113th CONGRESS</p></center>
<p/><center><p>1st Session</p></center>
<p/><center><p>H. R. 413</p></center>
<p>To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.</p><p/><center><p>IN THE HOUSE OF REPRESENTATIVES</p></center>
<p/><h3><center><p>January 23, 2013</p></center></h3>
<p>Mr. WELCH (for himself, Mr. HANNA, Mr. COOPER, and Mr. BRALEY of Iowa) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</p><hr/><p/><center><p>A BILL</p></center>
<p>To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.</p><ul><p><em>  Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,</em></p></ul><p/><h3>SECTION 1. ELIMINATING THE 2-YEAR DELAY IN IMPLEMENTATION OF ORAL-ONLY ESRD-RELATED DRUGS IN THE MEDICARE ESRD PROSPECTIVE PAYMENT SYSTEM.</h3>
<ul><p>Section 632(b) of the American Taxpayer Relief Act of 2012 (Public Law 112-240) is amended by striking all that precedes &#8216;With respect to the implementation&#8217; and inserting the following::</p><blockquote><p>&#8216;(b) Monitoring of Implementation of Oral-Only ESRD-Related Drugs in the ESRD Prospective Payment System- With respect to the implementation&#8217;.</p></blockquote></ul></body>